Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

HIV-1 Envelope Glycosylation and the Signal Peptide

Version 1 : Received: 7 February 2021 / Approved: 8 February 2021 / Online: 8 February 2021 (13:09:28 CET)

A peer-reviewed article of this Preprint also exists.

Lambert, G.S.; Upadhyay, C. HIV-1 Envelope Glycosylation and the Signal Peptide. Vaccines 2021, 9, 176. Lambert, G.S.; Upadhyay, C. HIV-1 Envelope Glycosylation and the Signal Peptide. Vaccines 2021, 9, 176.


The RV144 trial represents the only vaccine trial to demonstrate any protective effect against HIV-1 infection. While the reason(s) for this protection are still being evaluated, it serves as justification for widespread efforts aimed at developing new, more effective HIV-1 vaccines. Advances in our knowledge of HIV-1 immunogens and host antibody responses to these immunogens are crucial to informing vaccine design. While the envelope (Env) protein is the only viral protein present on the surface of virions, it exists in a complex trimeric conformation and is decorated with an array of variable N-linked glycans, making it an important but difficult target for vaccine design. Thus far, efforts to elicit a protective humoral immune response using structural mimics of native Env trimers have been unsuccessful. Notably, the aforementioned N-linked glycans serve as a component of many of the epitopes crucial for the induction of potentially protective broadly neutralizing antibodies (bnAbs). Thus, a greater understanding of Env structural determinants, most critically Env glycosylation, will no doubt be of importance in generating effective immunogens. Recent studies have identified the HIV-1 Env signal peptide (SP) as an important contributor to Env glycosylation. Further investigation into the mechanisms by which the SP directs glycosylation will be important, both in the context of understanding HIV-1 biology and in order to inform HIV-1 vaccine design.


HIV-1; HIV envelope; glycosylation; signal peptide; PNGs; broadly neutralizing antibodies; vaccine


Biology and Life Sciences, Virology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0

Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.